xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06040567</url>
    </required_header>
    <id_info>
      <org_study_id>H-23032160</org_study_id>
      <nct_id>NCT06040567</nct_id>
    </id_info>
    <brief_title>Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study</brief_title>
    <acronym>PolyImPAct</acronym>
    <official_title>Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Rigshospitalet, Denmark</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Rigshospitalet, Denmark</source>
    <oversight_info>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The project aims at investigating the validity, reliability of outcome measures of muscle&#xD;
        strength, functioning (gait, balance, and fine motor skills) and physical activity, as well&#xD;
        as patient reported outcome measures of functioning (gait, balance, and fine motor skills)&#xD;
        and daily living among patients with polyneuropathy. Further, the project aims at comparing&#xD;
        physical activity and patient reported outcome measures of functioning (gait, balance, and&#xD;
        fine motor skills) and daily living among patients with polyneuropathy with physical activity&#xD;
        and patient reported outcome measures of functioning (gait, balance, and fine motor skills)&#xD;
        and daily living in healthy adults.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        In four phases the investigators will evaluate physical activity and validity, reliability,&#xD;
        responsiveness of the outcome measures in patients with polyneuropathy. During the four&#xD;
        phases clinical outcome measures, patient reported outcomes measures, and accelerometer data&#xD;
        on physical activity will be evaluated. The investigators plan to include 400 adult patients&#xD;
        with polyneuropathy (acquired, hereditary, and idiopathic) from our clinic and 120 adult&#xD;
        healthy controls. The 400 patients with polyneuropathy include the following subtypes of&#xD;
        polyneuropathy: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), vasculitis&#xD;
        polyneuropathy, Polyneuropathy-Organomegaly-Endocrinopathy-Monoclonal protein-Skin changes&#xD;
        (POEMS syndrome), Multifocal Motor Neuropathy (MMN), Charcot Marie Tooth (CMT), hATTR&#xD;
        amyloidosis, Diabetic Polyneuropathy (DPN), and idiopathic neuropathy.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 25, 2023</start_date>
    <completion_date type="Anticipated">December 31, 2026</completion_date>
    <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
    <study_type>Observational</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Other</observational_model>
      <time_perspective>Prospective</time_perspective>
    </study_design_info>
    <primary_outcome>
      <measure>10-meter Walk Test</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>The patient is asked to 10 meter as fast as possible</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Six Spot Step Test</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>The patient is instructed to walk 5 meters as fast as possible, while kicking five cylinder blocks out of five circles marked on the floor.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>6-minute Walk Test</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>The patient will be asked to walk back and forth along a 25 meter walkway for six minutes. They will be instructed to walk as far as possible for six minutes.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>30 seconds Chair Stand Test</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>The patients will be asked to stand up and sit down as many times as possible in 30 secs with their arms across their chest</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Dynamic Gait Index</measure>
      <time_frame>At baseline, after 2-4 weeks, and after 1-2 years</time_frame>
      <description>The patient will be asked to walk while performing different tasks (walking: normally, while changing speed, while turning head (vertical and horizontal), while turning around, while stepping over obstacles, and walking stairs).</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Nine Hole Peg Test</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>Fine motor skills</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Jamar Hand-grip dynamometer (hand-grip-strength)</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>Best of three values</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Isometric strength measured with hand-held dynamometer</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>Will be tested bilateral at ankle, knee, wrist and elbow</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Isokinetic muscle strength measured with Biodex System 3 or 4 PRO, Biodex Medical Systems</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>Will be tested bilateral at ankle and knee</description>
    </primary_outcome>
    <primary_outcome>
      <measure>SENS motion activity sensor (accelerometer)</measure>
      <time_frame>At baseline (study entry), and after 1-2 years</time_frame>
      <description>The SENS motion activity sensor is a wearable accelerometer. It measures physical activity by collecting raw data of accelerations. Data on active time, sedentary time, time spent walking and number of steps taken will be collected.&#xD;
  The sensor will be attached and worn 24/7 (the sensor will be worn the week following baseline tests, and the week after tests at visit three (1-2 years after baseline).</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Inflammatory Neuropathy Cause and Treatment (INCAT)</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>Interview based disability scale INCAT evaluates disability of the upper and lower limb. The total INCAT score ranges from 0-10 (low scores indicating no disability and higher scores indicating higher level of disability).</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Rasch-build Overall Disability Scale for Immune-mediated peripheral neuropathies (I-RODS)</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>I-RODS is a 24-item patient reported outcome measure that measures disability. The raw score ranges from 0-48, with 0 indicating severe disability and higher scores indicating lower levels of disability.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Falls Efficacy Scale-International (FES-I)</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>Assesses limitations related to fear of falling. FES-I is a 16-item patient reported outcome measure that measures fear of falling. The score ranges from 16-64, with higher scores indicating greater fear of falling.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Composite Autonomic Symptom Score (COMPAS-31)</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>Assesses autonomic dysfunction Compass-31 is a patient reported outcome measure that measures autonomic dysfunction. Scores ranges from 0-100, with higher scores indicating more severe symptoms of autonomic dysfunction.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Self-reported Leeds Assessment of Neuropathic Symptoms and Signs (S-LANNS)</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>Assesses neuropathic pain S-LANSS is a patient reported outcome measure for identifying neuropathic pain.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Fatigue Severity Scale (FSS)</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>Assesses fatigue FSS is a 9-item patient reported outcome measure that measures fatigue, and the impact of fatigue on physical activity and daily living. The score ranges from 9-63, with a higher score indicating higher levels of fatigue.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>PittsburghSleep Quality Index</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>PittsburghSleep Quality Index is a patient reported outcome measure that assesses sleep quality. The score ranges from 0-21, with higher scores indicating more affected sleep quality</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Major Depression Inventory (MDI)</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>MDI is a patient reported outcome measure that measures depressive symptoms. The score ranges from 0-50, with higher scores indicating deeper depression.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>International Physical Activity Questionaire (IPAQ)</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>International Physical Activity Questionaire (IPAQ) is a patient reported outcome measure that measures physical activity.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Physical Activity Scale (PAS2)</measure>
      <time_frame>At baseline (study entry), after 2-4 weeks, and after 1-2 years</time_frame>
      <description>PAS2 is a 7-item patient reported outcome measure that measures physical activity and sedentary behavior.</description>
    </secondary_outcome>
    <number_of_groups>2</number_of_groups>
    <enrollment type="Anticipated">520</enrollment>
    <condition>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</condition>
    <condition>Vasculitic Neuropathy</condition>
    <condition>POEMS Syndrome</condition>
    <condition>Multifocal Motor Neuropathy</condition>
    <condition>Charcot-Marie-Tooth</condition>
    <condition>hATTR Amyloidosis</condition>
    <condition>Diabetic Polyneuropathy</condition>
    <condition>Idiopathic Neuropathy</condition>
    <condition>Polyneuropathies</condition>
    <arm_group>
      <arm_group_label>Patients with polyneuropathy</arm_group_label>
      <description>Adults (&gt; 18 years) diagnosed with polyneuropathy</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Healthy controls</arm_group_label>
      <description>Healthy adults (&gt;18 years)</description>
    </arm_group>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Validity and reliability of outcome measures in polyneuropathy</intervention_name>
      <description>Patients will be tested, answer patient reported outcome measures, and wear accelerometer at baseline after 2-4 weeks and after 1-2 years.</description>
      <arm_group_label>Patients with polyneuropathy</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Healthy controls</intervention_name>
      <description>Healthy controls will be tested, answer patient reported outcome measures, and wear accelerometer at baseline visit. There is no follow-up in the healthy control group.</description>
      <arm_group_label>Healthy controls</arm_group_label>
    </intervention>
    <eligibility>
      <study_pop>
        <textblock>
          Patients will be recruited from a the neuromuscular clinic at Rigshopitalet, Copenjagen,&#xD;
          Denmark&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Non-Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
          Inclusion Criteria patients:&#xD;
  &#xD;
          &gt; 18 years Diagnosed with polyneuropathy (verified by nerve conduction)&#xD;
  &#xD;
          Inclusion Criteria healthy controls:&#xD;
  &#xD;
          &gt; 18 years Healthy&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
          Exclusion Criteria patients:&#xD;
  &#xD;
          Not verified polyneuropathy&#xD;
  &#xD;
          Exclusion Criteria healthy controls:&#xD;
  &#xD;
          Diabetes, brain-, nerve-, muscle-, kidney-, or liver disease. Diagnosed with polyneuropathy&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>100 Years</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Britt S Pedersen</last_name>
      <role>Study Chair</role>
      <affiliation>Rigshospitalet, University of Copenhagen</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Britt S Pedersen</last_name>
      <phone>+4535458401</phone>
      <email>britt.staevnsbo.pedersen.01@regionh.dk</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Tina Dysgaard</last_name>
      <email>tina.dysgaard@regionh.dk</email>
    </overall_contact_backup>
    <verification_date>September 2023</verification_date>
    <study_first_submitted>September 1, 2023</study_first_submitted>
    <study_first_submitted_qc>September 8, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 15, 2023</study_first_posted>
    <last_update_submitted>September 8, 2023</last_update_submitted>
    <last_update_submitted_qc>September 8, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 15, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
      <investigator_full_name>Britt Stævnsbo Pedersen</investigator_full_name>
      <investigator_title>PhD Fellow</investigator_title>
    </responsible_party>
    <keyword>Polyneuropathy</keyword>
    <keyword>Clinical outcome measures</keyword>
    <keyword>Patient reported outcome measures (PROMs)</keyword>
    <keyword>Physical activity</keyword>
    <keyword>Accelerometer</keyword>
    <keyword>Validity</keyword>
    <keyword>Reliability</keyword>
    <keyword>Responsiveness</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Polyneuropathies</mesh_term>
      <mesh_term>Charcot-Marie-Tooth Disease</mesh_term>
      <mesh_term>Nerve Compression Syndromes</mesh_term>
      <mesh_term>Hereditary Sensory and Motor Neuropathy</mesh_term>
      <mesh_term>Diabetic Neuropathies</mesh_term>
      <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
      <mesh_term>POEMS Syndrome</mesh_term>
      <mesh_term>Amyloidosis</mesh_term>
    </condition_browse>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06040567
  org study id: H-23032160
  nct id: NCT06040567
  lead sponsor: 
  is fda regulated drug: No
  is fda regulated device: No
  The project aims at investigating the validity, reliability of outcome measures of muscle
        strength, functioning (gait, balance, and fine motor skills) and physical activity, as well
        as patient reported outcome measures of functioning (gait, balance, and fine motor skills)
        and daily living among patients with polyneuropathy. Further, the project aims at comparing
        physical activity and patient reported outcome measures of functioning (gait, balance, and
        fine motor skills) and daily living among patients with polyneuropathy with physical activity
        and patient reported outcome measures of functioning (gait, balance, and fine motor skills)
        and daily living in healthy adults.
  In four phases the investigators will evaluate physical activity and validity, reliability,
        responsiveness of the outcome measures in patients with polyneuropathy. During the four
        phases clinical outcome measures, patient reported outcomes measures, and accelerometer data
        on physical activity will be evaluated. The investigators plan to include 400 adult patients
        with polyneuropathy (acquired, hereditary, and idiopathic) from our clinic and 120 adult
        healthy controls. The 400 patients with polyneuropathy include the following subtypes of
        polyneuropathy: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), vasculitis
        polyneuropathy, Polyneuropathy-Organomegaly-Endocrinopathy-Monoclonal protein-Skin changes
        (POEMS syndrome), Multifocal Motor Neuropathy (MMN), Charcot Marie Tooth (CMT), hATTR
        amyloidosis, Diabetic Polyneuropathy (DPN), and idiopathic neuropathy.
  observational model: Other
  time perspective: Prospective
  measure: 10-meter Walk Test
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: The patient is asked to 10 meter as fast as possible
  measure: Six Spot Step Test
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: The patient is instructed to walk 5 meters as fast as possible, while kicking five cylinder blocks out of five circles marked on the floor.
  measure: 6-minute Walk Test
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: The patient will be asked to walk back and forth along a 25 meter walkway for six minutes. They will be instructed to walk as far as possible for six minutes.
  measure: 30 seconds Chair Stand Test
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: The patients will be asked to stand up and sit down as many times as possible in 30 secs with their arms across their chest
  measure: Dynamic Gait Index
  time frame: At baseline, after 2-4 weeks, and after 1-2 years
  description: The patient will be asked to walk while performing different tasks (walking: normally, while changing speed, while turning head (vertical and horizontal), while turning around, while stepping over obstacles, and walking stairs).
  measure: Nine Hole Peg Test
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: Fine motor skills
  measure: Jamar Hand-grip dynamometer (hand-grip-strength)
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: Best of three values
  measure: Isometric strength measured with hand-held dynamometer
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: Will be tested bilateral at ankle, knee, wrist and elbow
  measure: Isokinetic muscle strength measured with Biodex System 3 or 4 PRO, Biodex Medical Systems
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: Will be tested bilateral at ankle and knee
  measure: SENS motion activity sensor (accelerometer)
  time frame: At baseline (study entry), and after 1-2 years
  description: The SENS motion activity sensor is a wearable accelerometer. It measures physical activity by collecting raw data of accelerations. Data on active time, sedentary time, time spent walking and number of steps taken will be collected.
  The sensor will be attached and worn 24/7 (the sensor will be worn the week following baseline tests, and the week after tests at visit three (1-2 years after baseline).
  measure: Inflammatory Neuropathy Cause and Treatment (INCAT)
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: Interview based disability scale INCAT evaluates disability of the upper and lower limb. The total INCAT score ranges from 0-10 (low scores indicating no disability and higher scores indicating higher level of disability).
  measure: Rasch-build Overall Disability Scale for Immune-mediated peripheral neuropathies (I-RODS)
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: I-RODS is a 24-item patient reported outcome measure that measures disability. The raw score ranges from 0-48, with 0 indicating severe disability and higher scores indicating lower levels of disability.
  measure: Falls Efficacy Scale-International (FES-I)
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: Assesses limitations related to fear of falling. FES-I is a 16-item patient reported outcome measure that measures fear of falling. The score ranges from 16-64, with higher scores indicating greater fear of falling.
  measure: Composite Autonomic Symptom Score (COMPAS-31)
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: Assesses autonomic dysfunction Compass-31 is a patient reported outcome measure that measures autonomic dysfunction. Scores ranges from 0-100, with higher scores indicating more severe symptoms of autonomic dysfunction.
  measure: Self-reported Leeds Assessment of Neuropathic Symptoms and Signs (S-LANNS)
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: Assesses neuropathic pain S-LANSS is a patient reported outcome measure for identifying neuropathic pain.
  measure: Fatigue Severity Scale (FSS)
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: Assesses fatigue FSS is a 9-item patient reported outcome measure that measures fatigue, and the impact of fatigue on physical activity and daily living. The score ranges from 9-63, with a higher score indicating higher levels of fatigue.
  measure: PittsburghSleep Quality Index
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: PittsburghSleep Quality Index is a patient reported outcome measure that assesses sleep quality. The score ranges from 0-21, with higher scores indicating more affected sleep quality
  measure: Major Depression Inventory (MDI)
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: MDI is a patient reported outcome measure that measures depressive symptoms. The score ranges from 0-50, with higher scores indicating deeper depression.
  measure: International Physical Activity Questionaire (IPAQ)
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: International Physical Activity Questionaire (IPAQ) is a patient reported outcome measure that measures physical activity.
  measure: Physical Activity Scale (PAS2)
  time frame: At baseline (study entry), after 2-4 weeks, and after 1-2 years
  description: PAS2 is a 7-item patient reported outcome measure that measures physical activity and sedentary behavior.
  arm group label: Patients with polyneuropathy
  description: Adults (> 18 years) diagnosed with polyneuropathy
  arm group label: Healthy controls
  description: Healthy adults (>18 years)
  intervention type: Other
  intervention name: Validity and reliability of outcome measures in polyneuropathy
  description: Patients will be tested, answer patient reported outcome measures, and wear accelerometer at baseline after 2-4 weeks and after 1-2 years.
  arm group label: Patients with polyneuropathy
  intervention type: Other
  intervention name: Healthy controls
  description: Healthy controls will be tested, answer patient reported outcome measures, and wear accelerometer at baseline visit. There is no follow-up in the healthy control group.
  arm group label: Healthy controls
  study pop: 
  sampling method: Non-Probability Sample
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 100 Years
  healthy volunteers: Accepts Healthy Volunteers
  last name: Britt S Pedersen
  role: Study Chair
  affiliation: Rigshospitalet, University of Copenhagen
  last name: Britt S Pedersen
  phone: +4535458401
  email: britt.staevnsbo.pedersen.01@regionh.dk
  last name: Tina Dysgaard
  email: tina.dysgaard@regionh.dk
  responsible party type: Principal Investigator
  investigator affiliation: Rigshospitalet, Denmark
  investigator full name: Britt Stævnsbo Pedersen
  investigator title: PhD Fellow
  mesh term: Polyneuropathies
  mesh term: Charcot-Marie-Tooth Disease
  mesh term: Nerve Compression Syndromes
  mesh term: Hereditary Sensory and Motor Neuropathy
  mesh term: Diabetic Neuropathies
  mesh term: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
  mesh term: POEMS Syndrome
  mesh term: Amyloidosis